Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Eradication of melanomas by targeted elimination of a minor subset of tumor cells.

Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2474-9. doi: 10.1073/pnas.1009069108. Epub 2011 Jan 31.

PMID:
21282657
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M.

Cancer Cell. 2010 Dec 14;18(6):683-95. doi: 10.1016/j.ccr.2010.11.023.

PMID:
21156289
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.

Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.

PMID:
21107323
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.

Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.

PMID:
21107320
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.

Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ.

Cancer Cell. 2010 Nov 16;18(5):510-23. doi: 10.1016/j.ccr.2010.10.012.

PMID:
21075313
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Inhibition of mutated, activated BRAF in metastatic melanoma.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.

N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.

PMID:
20818844
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.

Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Longaker MT, Weissman IL.

Nature. 2010 Jul 1;466(7302):133-7. doi: 10.1038/nature09161. Erratum in: Nature. 2011 Feb 17;470(7334):424.

PMID:
20596026
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M.

Cell. 2010 May 14;141(4):583-94. doi: 10.1016/j.cell.2010.04.020.

PMID:
20478252
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Mutation-driven drug development in melanoma.

Flaherty KT, Hodi FS, Bastian BC.

Curr Opin Oncol. 2010 May;22(3):178-83. Review.

PMID:
20401974
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Heterogeneity in cancer: cancer stem cells versus clonal evolution.

Shackleton M, Quintana E, Fearon ER, Morrison SJ.

Cell. 2009 Sep 4;138(5):822-9. doi: 10.1016/j.cell.2009.08.017.

PMID:
19737509
[PubMed - indexed for MEDLINE]
Free Article
11.

Looking ahead in cancer stem cell research.

Dick JE.

Nat Biotechnol. 2009 Jan;27(1):44-6. doi: 10.1038/nbt0109-44. No abstract available.

PMID:
19131997
[PubMed - indexed for MEDLINE]
12.

Efficient tumour formation by single human melanoma cells.

Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ.

Nature. 2008 Dec 4;456(7222):593-8. doi: 10.1038/nature07567.

PMID:
19052619
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Identification of cells initiating human melanomas.

Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH.

Nature. 2008 Jan 17;451(7176):345-9. doi: 10.1038/nature06489.

PMID:
18202660
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15.

PMID:
17062687
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Melanoma.

Miller AJ, Mihm MC Jr.

N Engl J Med. 2006 Jul 6;355(1):51-65. Review. No abstract available.

PMID:
16822996
[PubMed - indexed for MEDLINE]
16.

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E.

J Clin Oncol. 2006 May 1;24(13):e20-2. No abstract available.

PMID:
16648493
[PubMed - indexed for MEDLINE]
Free Article
17.

A tumorigenic subpopulation with stem cell properties in melanomas.

Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M.

Cancer Res. 2005 Oct 15;65(20):9328-37.

PMID:
16230395
[PubMed - indexed for MEDLINE]
Free Article
18.
19.

CD20: a regulator of cell-cycle progression of B lymphocytes.

Tedder TF, Engel P.

Immunol Today. 1994 Sep;15(9):450-4. Review.

PMID:
7524522
[PubMed - indexed for MEDLINE]
20.

Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1.

Chattopadhyay P, Kaveri SV, Byars N, Starkey J, Ferrone S, Raychaudhuri S.

Cancer Res. 1991 Nov 15;51(22):6045-51.

PMID:
1933867
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk